BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 26, 2007
 |  BioCentury  |  Finance

Ebb & Flow Focus

Actelion Ltd. (SWX:ATLN) shed $615 million in market value last week, despite reporting that 2006 EPS jumped 85%, as investors apparently have some concerns about what’s ahead for the company.

Revenues and EPS have been driven by Tracleer bosentan for pulmonary arterial hypertension. But as Tracleer growth slows, the company’s earnings growth is doing the same, even without potential upcoming competition from ambrisentan from Gilead Sciences Inc. (GILD), which has the same mechanism of action and has a June 18 PDUFA date.

EPS jumped to CHF10.25 in 2006 over CHF5.54 in 2005 and revenues grew 43% in 2006 to CHF945.7 million ($775.5 million). But the stock fell CHF33.50 (11%) on the week to CHF276, leaving ATLN’s market cap at $5.1 billion (see "EPS Watch,"...

Read the full 619 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >